Featured Articles:

An Unclear Email and a Revoked License: What Rice Lake’s $60,764 OFAC Settlement Teaches About Foreign Subsidiaries

OFAC’s settlement with Rice Lake Weighing Systems is a small-dollar case, just $60,764, but it is an unusually instructive one, because it captures almost every classic failure mode in how U.S. companies manage sanctions compliance at their foreign subsidiaries: a license that got revoked, an instruction that didn’t translate into real understanding, and a subsidiary that kept dealing with a sanctioned country indirectly after being...

DOJ’s New Fraud Division Memo: A Roadmap to Where Enforcement Is Actually Headed

The Justice Department rarely hands compliance officers a document that spells out its enforcement priorities this directly, but that’s essentially what Assistant Attorney General Colin McDonald did this week in a memo to staff of the newly formed National Fraud Enforcement Division. The memo is worth reading in full, because it functions less like an internal org chart announcement and more like a public roadmap...

Episode 445 — Why Your Organization Needs an AI Acceptable Use Policy

In this episode of Corruption, Crime and Compliance, Michael Volkov makes the case that every organization needs a written AI Acceptable Use Policy now, not eventually, because employees are already using AI tools with or without formal governance. He walks through the three core risk categories driving that urgency: confidentiality exposure when employees submit sensitive data to ungoverned tools, hallucination risk from AI-generated content that...

Veloxis Pharmaceuticals’ $46 Million Kickback Settlement: A CEP Case Study Worth Studying Closely

Veloxis Pharmaceuticals, the maker of the kidney transplant immunosuppression drug Envarsus XR, has agreed to pay more than $46 million and submit to years of enhanced compliance oversight to resolve civil and criminal allegations that the company ran a sustained kickback scheme to drive prescriptions of its drug. This case is worth a close read for compliance officers well beyond the pharmaceutical industry, because it’s...

Can Your Biggest FCPA Risk Be a Trusted Insider?

Have you heard about the Goldman Sachs banker who bribed his way to a conviction? A federal jury in Brooklyn last week convicted Asante Berko, a former Goldman Sachs executive, on FCPA conspiracy, a substantive FCPA violation, and money laundering conspiracy. Berko managed a deal between a Turkish energy company and the government of Ghana to build a new power plant in Ghana. To win...

The U.S. Launches a New Iran Sanctions Campaign and Suspends General Licenses: What Compliance Programs Need to Know Now

The Treasury Department rolled out a significant escalation of its Iran sanctions program on August 24, and this one is worth immediate attention from any organization with even indirect exposure to Iran-related activity, because it combines two things that don’t usually arrive together: a large batch of new designations and a suspension of general licenses that companies may have been relying on for years to...

The $1 Million Lesson in Container Manufacturing’s Russia Export Case: Ignored Red Flags Are Their Own Violation

BIS just settled with Container Manufacturing, an Ohio-based maker of tops for aluminum beverage cans, for $1 million over ten violations of U.S. export controls tied to Russia. On the surface, this looks like a modest regional manufacturer case involving unglamorous industrial spare parts. Underneath, it’s one of the clearest illustrations I’ve seen this year of a principle every compliance officer needs to internalize: a...

Is Trade Fraud the Next Major False Claims Act Risk?

If you think your company can smuggle and fly under the radar screen, think again. When your company touches imports, customs, or tariffs, you need to know this. The Justice Department stood up a dedicated trade fraud task force in August of last year. Its first settlement came three months later. This past May, it delivered the largest customs-related False Claims Act recovery ever: $550...

Plexon’s $1.7 Million Export Settlement: Brain-Computer Interfaces, China’s Military, and a Warning About Emerging Tech Controls

The Commerce Department’s Bureau of Industry and Security announced a settlement with Plexon Inc., a Dallas-based neuroscience company, over eight unlicensed exports of brain-computer interface equipment to a Chinese research institute with direct ties to the People’s Liberation Army. This case deserves attention well beyond the neuroscience and export control communities, because it illustrates exactly how emerging technology controls are catching companies that may not...

L3Harris Ousts Kubasik Over Code-of-Conduct Violation: The Board Governance Lesson Nobody Wants to Learn Twice

L3Harris Technologies parted ways with its chairman and CEO, Christopher Kubasik, after an internal investigation determined he had violated the company’s code of conduct. The company hasn’t detailed the specific conduct at issue, and it went out of its way to state that the departure had nothing to do with financial reporting or operational performance. The market reacted anyway: L3Harris shares dropped nearly 5 percent...